New cancer diagnostic method unravels the complexity of breast cancer tumors

November 18, 2016 by Allison Huseman
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

A team of researchers at Baylor College of Medicine, the University of Pittsburgh Cancer Institute, RainDance Technologies, Inc., and Mayo Clinic College of Medicine and Science has developed a novel computational approach to unravel the complexity of breast cancer tumors. The strategy allows researchers to identify the different types of cells in the tumor and to unveil how the interactions between cancer and normal cells may shape the fate of the tumor. The results appear in Cell Reports.

"We have developed a computational method that allows us to better understand what goes on inside a tumor," said first author Vitor Onuchic, who is a graduate student in the Program in Structural and Computational Biology and Molecular Biophysics at Baylor in the Bioinformatics Research Laboratory. "We can infer the cell type composition of breast tumors, detecting both normal and cancerous cell types. We can also detect changes in the epigenomic and transcriptomic profiles of individual cell types, which indicate what parts of the genome – the genetic makeup of the cell – become activated or inactivated within each cell type, as the cancer progresses."

A tumor behaves like a community; it comprises different types of cells, cancerous and normal, that interact with each other. The result of these interactions can be tumor growth or tumor elimination. Understanding the cellular composition and the cell interactions that tip the balance in favor of tumor elimination or growth can open doors for developing improved therapies.

"Without understanding the composition of tumors we couldn't understand how cells engage in that disease-causing exchange of information," said senior author Dr. Aleksandar Milosavljevic, professor of molecular and human genetics and director of the Program in Structural and Computational Biology and Molecular Biophysics at Baylor. "By mapping cell-type composition and epigenomic changes we can better understand what is it that cells do to each other to promote cancer."

The advantages of the new approach and major findings

"Previous approaches that looked at specific cell types within a tumor applied laboratory methods that physically separate and identify the different cell types," said Onuchic. "This can be difficult, costly and time consuming, and preclude analyzing large numbers of cells. Another downside of this approach is that physically separating the different types of cells disrupts the interactions between the cells within the tissue, something we want to understand."

With the new computational approach the researchers are able to look at how these cells interact in their native microenvironment without having to physically separate the different .

"In addition, our approach allows us to look at a large number of tumor samples," said Onuchic. "We can reanalyze numerous data we already generated from tumors and extract different types of information from the same dataset without having to go back and process the original samples."

With this new approach the researchers were able to estimate the level of immune cell infiltration within the tumor in a large collection of breast samples from the Cancer Genome Atlas. They saw that for particular subtypes of breast tumors a higher level of immune cell infiltration resulted in better patient survival. The researchers also discovered that a shift from adipose (fatty) to fibrotic tissue creates a microenvironment rich in compounds that feed the growth of cancer .

"I am very excited about applying this type of new analysis to different types of tumors," said Onuchic.

A part of the International Human Epigenome Consortium

This work is part of a collection of 41 papers published simultaneously by researchers from the International Human Epigenome Consortium (IHEC), which is at the vanguard of epigenomic research. The papers represent the most recent work by members of the consortium which are located in Canada, the European Union, Germany, Japan, Singapore and the United States.

"IHEC is the only international 'omics' consortium after the International Cancer Genome Consortium that has produced a bolus of joint publications of this kind," said Milosavljevic. "My laboratory at Baylor was the Data Analysis and Coordination Center for the National Institutes of Health Roadmap Epigenome Consortium, which catalyzed the formation of IHEC and contributed the know-how to help launch the international projects. As a member of the Steering Committee of the Consortium, my continuous efforts over the last five years helped start the Consortium and led it to this point."

Explore further: New subtypes of lung cancer can lead to personalized therapies with better outcome

More information: Vitor Onuchic et al. Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types, Cell Reports (2016). DOI: 10.1016/j.celrep.2016.10.057

Related Stories

New subtypes of lung cancer can lead to personalized therapies with better outcome

October 24, 2016
Personalized therapies can potentially improve the outcomes of patients with lung cancer, but how to best design such an approach is not always clear. A team of scientists from Baylor College of Medicine and the University ...

Once inside a tumor, our immune cells become traitors

November 15, 2016
New research has found a subset of our immune cells (called regulatory T cells) that are highly abundant in the tumor microenvironment and are particularly good at suppressing the anticancer immune response. In two independent ...

Single-cell analysis supports a role for cancer stem cells in brain tumor growth

November 2, 2016
A study analyzing brain tumor genomics on a single-cell level has found evidence that cancer stem cells fuel the growth of oligodendrogliomas, a slow-growing but incurable form of brain cancer. In their paper receiving advance ...

Breast cancer tumor-initiating cells use mTOR signaling to recruit suppressor cells to promote tumor

May 16, 2016
Not every breast cancer tumor follows the same path to grow. Some tumors have the assistance of myeloid-derived suppressor cells (MDSCs), a diverse type of immune cell involved in the suppression of the body's response against ...

Depleting CAR T cells after tumor treatment reverses B cell deficiency in mice

October 17, 2016
Genetically engineered T cells, or CAR T cells, represent a promising approach to treat multiple types of cancer. These therapies can eliminate tumors by targeting specific markers that are expressed on different cancer cell ...

Uncovering the mechanisms that support the spread of ovarian cancer

October 10, 2016
A very high mortality rate is associated with ovarian cancer, in part due to difficulties in detecting and diagnosing the disease at early stages before tumors have spread, or metastasized, to other locations in the body.

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.